Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 8;5(12):e1254856.
doi: 10.1080/2162402X.2016.1254856. eCollection 2016.

PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

T Jelinek  1 , R Hajek  2
Affiliations
Review

PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

T Jelinek et al. Oncoimmunology. .

Abstract

The introduction of PD-1/PD-L1 pathway inhibitors has marked a significant milestone in the treatment of various types of solid tumors. The current situation in multiple myeloma (MM) is rather unclear, as distinct research groups have reported discordant results. This discrepancy dominantly concerns the expression of PD-1/PD-L1 molecules as well as the identification of the responsible immune effector cell population. The results of monotherapy with PD-1/PD-L1 inhibitors have been unsatisfactory in MM, suggesting that a combination approach is needed. The most logical partners are immunomodulatory agents as they possess many synergistic effects. We are also proposing other rational and promising combinations (e.g., daratumumab, ibrutinib, anti-CD137) that warrant further investigation.

Keywords: Daratumumab; PD-1; PD-L1; durvalumab; ibrutinib; irradiation; multiple myeloma; nivolumab; pembrolizumab; pidilizumab.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mechanism of action of PD-1/PD-L1 inhibitors and potential synergism with IMiDs.
See this image and copyright information in PMC

References

    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046-60; PMID:21410373; http://dx.doi.org/ 10.1056/NEJMra1011442 - DOI - PubMed
    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/24157580 10.3322/caac.21208 - DOI - PubMed
    1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N et al.. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28:1122-8; PMID:24157580; http://dx.doi.org/ 10.1038/leu.2013.313 - DOI - PMC - PubMed
    1. San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A et al.. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14:1055-66; PMID:24007748; http://dx.doi.org/ 10.1016/S1470-2045(13)70380-2 - DOI - PubMed
    1. San-Miguel JF, Hungria VTM, Yoon S-S, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N et al.. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15:1195-206; PMID:25242045; http://dx.doi.org/ 10.1016/S1470-2045(14)70440-1 - DOI - PubMed

Publication types